News

Philippe GARABEDIAN (TBS 2005) - Myriade, innovative start-up in the health sector

18 June 2020 Association

Philippe GARABEDIAN (TBS 2005) became Director of Operations at Myriade in October 2019

About Myriade, a fast growing start-up with an innovative approach to the health sector:

Cellular and gene therapies are booming. Using viruses, or in more scientific language, viral vectors, genetic material is introduced into the patient's defective cells to correct the genetic defect or fight against disease. 

It is key to check the efficiency and safety of this new medication. It is essential to precisely determine the concentration of the virus (dose) and the purity of the solution. However, these viruses are invisible with standard optical techniques. They are the size of nanoparticles.

Today, in the absence of a solution to continuously control the entire bioproduction chain, Biotech companies work blindly for 4 weeks (cost = 500k€). There is a very real need for an in-process quality control method for the industrial development of viral vector batches in cellular and gene therapies.

Myriade, a French company created in 2017, is developing innovative image technology on a nanometric scale : the VIDEODROP. Based on the principles of interferometry, Videodrop provides the means of measuring the size and concentration of nanoparticles between 30 nm and 10 microns without marking, in real time (6s) and in a single drop (5µL).

Operational Management 

Myriade's ambition is to make Videodrop the ideal system for quick in-process control for complex solutions of nanoparticles containing viruses, phages, extra-cellular vesicles, etc. and in this way become the reference tool in bioproduction of innovative medication. 

Within this scope, Philippe GARABEDIAN joined Myriade 6 months ago to take over the responsibility for operational management of the company (start-up) and more in particular, business development, marketing, development strategy implementation ! 

We wish him all the best ! 




Love it

No comment

Log in to post comment. Log in.